Partnership for first-in-class cancer and CRM treatments
Boehringer Ingelheim partners with OSE Immunotherapeutics to develop first-in-class cancer and CRM treatments
Search
ivomec
Depending on formulation, the product is for the treatment of nematodes, lice, mites, ticks, flies, lungworms and liver flukes.
Eprinex®
Depending on formulation, the product is for the treatment of nematodes, lice, mites, ticks, flies and lungworms in cattle and sheep.
Our core product areas
Acquisition expands research in cancer immunology
Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
FRONTLINE® becomes Brand of the Year 2021-22
FRONTLINE® becomes Brand of the Year 2021-2022 in World Branding Awards
Introducing Karl and Klara Kidney
Kidney disease and type 2 diabetes are closely linked, and share many of the same risk factors and pathological pathways
Heart Diseases in humans and animals
Humans and animals are more alike than different. Having a heart disease can affect us similarly, and the way to prevent it can work for all as well.
Boehringer and ZEISS partnership eye diseases
Boehringer Ingelheim and ZEISS join forces to early detect eye diseases and prevent vision loss
SPEVIGO approved expanded indications China US
SPEVIGO® approved for expanded indications in China and the US
FRONTLINE becomes Brand of the Year 2019-2020
FRONTLINE becomes ‘Brand of the Year’ 2019-2020 in World Branding Awards
Boehringer-Ingelheim's-half-year-figures-2021
Press release on Boehringer Ingelheim's half-year figures 2021. Business development from January to June 2021.
Acquisition Saint-Herblon site and Coophavet brand
Boehringer Ingelheim and Dopharma complete the acquisition of Saint-Herblon production site
Heart murmur in dogs: symptoms and how to treat it
Monitoring your dog’s heart can save its life
“Rapid progress towards clinical candidates”
Boehringer Ingelheim forms a joint venture to create the next generation of antimicrobials.
How to create a supplier standard Ariba account
How to create an Ariba standard account processing a purchas
Driving environmental solutions for people and planet
In 2022, Boehringer Ingelheim's MORE GREEN environmental sustainability initiative has reached new milestones driving our global decarbonization efforts
How Boehringer Ingelheim has responded to the pandemic
As part of the pharmaceutical industry, Boehringer Ingelheim joined the collective efforts in fighting COVID-19 ever since the start of the pandemic.
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
Ukraine Help: In a nine-seater to Poland
Boehringer Ingelheim employee Eugen Pushchyk rescues refugees from Ukraine
Monoclonal antibodies Boehringer Ingelheim and Invetx
Boehringer Ingelheim and Invetx announce collaboration to discover, develop and commercialize novel veterinary monoclonal antibody biotherapeutics
Mental Health and the Value of Connection
Yammie and Jurgen share their story of friendship, and how much they value connection as people living with mental health conditions.
International Women’s Day: gender and health equity
On International Women’s Day, we join forces to collectively strive for gender and health equity, empowering women in and beyond our company.
EMA filing acceptance and validation for spesolimab
The European Medicines Agency has accepted and validated the marketing authorization application for spesolimab in generalized pustular psoriasis